Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series

Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series

In Russia, the interleukin-1 inhibitor canakinumab (fully human monoclonal antibodies to interleukin-1) is increasingly used for treating autoinflammatory diseases and systemic juvenile arthritis (sJIA). The article describes the experience of administering canakinumab in patients with autoinflammat...

Full description

Bibliographic Details
Main Authors:	S. O. Salugina, M. I. Kaleda, Ye. S. Fyodorov, I. P. Nikishina
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2016-02-01
Series:	Voprosy Sovremennoj Pediatrii
Subjects:	autoinflammatory diseases systemic juvenile arthritis treatment interleukin-1 inhibitors canakinumab
Online Access:	https://vsp.spr-journal.ru/jour/article/view/1586

Similar Items

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016-11-01)

Experience of the successful treatment with canakinumab of a patient with NLPC4-associated autoinflammatory syndrome with enterocolitis
by: T. V. Sleptsova, et al.
Published: (2016-06-01)

Results of molecular genetic screening of mutations in the NLRP3, TNFRSF1A, and MVK genes in patients with autoinflammatory diseases and systemic juvenile arthritis
by: S. O. Salugina, et al.
Published: (2017-09-01)

Nullius in verba: "Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes" in NEJM
by: Sinan Kardeş
Published: (2019-02-01)

CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-09-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

Experience of the Successful Treatment With Canakinumab of a Patient With Systemic Juvenile Idiopathic Arthritis
by: Ekaterina I. Alexeeva, et al.
Published: (2017-06-01)

Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab
by: S O Salugina, et al.
Published: (2017-11-01)

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
by: E. I. Alexeeva, et al.
Published: (2014-03-01)

Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases
by: Alessandra Bettiol, et al.
Published: (2019-04-01)

A familial case of Muckle-Wells syndrome in a Russian population: The first successes of therapy with the interleukin 1 inhibitor canakinumab
by: S. O. Salugina, et al.
Published: (2015-03-01)

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
by: Yuya Fujita, et al.
Published: (2021-03-01)

EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
by: Maksim Sergeyevna Eliseev, et al.
Published: (2014-03-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

Myositis in the course of the systemic form juvenile idiopathic arthritis
by: Piotr Gietka, et al.
Published: (2014-06-01)

Autoinflammatory Mechanisms in Crystal-Induced Arthritis
by: Francesca Oliviero, et al.
Published: (2020-04-01)

Therapy with canakinumab for gout
by: M. S. Eliseev, et al.
Published: (2019-04-01)

Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
by: Antonio Vitale, et al.
Published: (2019-04-01)

Canakinumab for refractory RA: a case report
by: Nikolaos Marketos, et al.
Published: (2018-01-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis
by: Najla Aljaberi, et al.
Published: (2020-01-01)

AUTOINFLAMMATORY DISEASES IN RHEUMATOLOGY: RUSSIAN EXPERIENCE
by: S. O. Salugina, et al.
Published: (2016-07-01)

Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used
by: M. S. Eliseev, et al.
Published: (2015-06-01)

Therapy with canakinumab for adult-onset still's disease
by: E. L. Nasonov
Published: (2019-04-01)

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
by: Hana Malcova, et al.
Published: (2021-01-01)

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)
by: M. Bielak, et al.
Published: (2018-04-01)

Treating TRAPS Syndrome with a Previously Undescribed TNF α Gene Receptor Mutation Successfully with Canakinumab
by: T. V. Sleptsova, et al.
Published: (2016-11-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

Low-penetrance R92Q (p.Arg121Gln) mutation in the <i>TNFRSF1A</i> gene: the significance and variants of phenotypes. Successful experience with the interleukin-1 inhibitor canakinumab in a female patient, who is a carrier of R92Q mutation with a severe TRAPS phenotype
by: E. S. Fedorov, et al.
Published: (2020-09-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
by: A. L. Kozlova, et al.
Published: (2015-04-01)

Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide
by: Alessandra Soriano, et al.
Published: (2020-06-01)

Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms
by: Hanna Bonnekoh, et al.
Published: (2020-03-01)

Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2020-08-01)

Role of interleukin 1 in the development of atherosclerosis
by: E. L. Nasonov, et al.
Published: (2019-04-01)

Management of Mevalonate Kinase Deficiency: A Pediatric Perspective
by: Jerold Jeyaratnam, et al.
Published: (2020-06-01)

Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype
by: S. L. N. Clarke, et al.
Published: (2020-05-01)

Gene engineering biological therapy for juvenile arthritis
by: Kh Mikhel's, et al.
Published: (2011-02-01)

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives
by: Toplak N, et al.
Published: (2018-06-01)